Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Taylor & Francis. In 2021 the journal stated that it had an impact factor of 3.912.[1]
 | |
| Discipline | Pharmacology |
|---|---|
| Language | English |
| Edited by | Claire Attwood |
| Publication details | |
Former name(s) | Emerging Drugs |
| History | 1996–present |
| Publisher | |
| Frequency | Quarterly |
| 3.912 (2021) | |
| Standard abbreviations | |
| ISO 4 | Expert Opin. Emerg. Drugs |
| Indexing | |
| ISSN | 1472-8214 (print) 1744-7623 (web) |
| Links | |
References edit
- ^ From journal Web site
External links edit
  | This article about a pharmacology journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |